BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)


You May Also Like

OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products

Key Clinical Portfolio Development Progress Planned for 2018              Tedopi® (neoepitopes): Phase 3 clinical trial in ...